MichaelWilliamLattanziMD

Oncology • Austin, TX

Genitourinary Oncology

Physician

Join to view full profile

Dr. Lattanzi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lattanzi's full profile

Already have an account?

Office
6204 Balcones Dr
Austin, TX 78731
Phone+1 512-427-9400

Fax+1 512-342-2723

Summary

Genitourinary Medical Oncology & Clinical Trials

Education & Training

NYU Grossman School of MedicineResidency, Internal Medicine, 2016 - 2019
New York University School of MedicineClass of 2016

Certifications & Licensure

TX State Medical License 2022 - 2025
NC State Medical License 2022 - 2023
NY State Medical License 2019 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

29 citations
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Samuel A Funt, Michael Lattanzi, Karissa Whiting, Hikmat Al-Ahmadie, Colleen Quinlan
Journal of Clinical Oncology. 2022-04-20
11 citations
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
Michael Lattanzi, Joseph Han, Una Moran, Kierstin Utter, Jeremy Tchack
Journal for Immunotherapy of Cancer. 2018-05-18
40 citations
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma
Anna C. Pavlick, Ana Belen Blazquez, Marcia Meseck, Michael Lattanzi, Patrick A. Ott
Cancer Immunology Research. 2020-01-01

Lectures

Single cell analysis of urothelial carcinoma (UC) liver metastases identifies epithelial-mesenchymal transition (EMT) as a potential mechanism of resistance to immunot...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

ESMO 2019: TROPHY-U-01: Initial Results of a Phase 2 Open-Label Study of Sacituzumab Givotecan in Patients with Metastatic Urothelial Cancer After Failure of Platinum-Based Regimens or ImmunotherapySeptember 29th, 2019
ESMO 2019: Single Agent Immune Therapy and Immune CombinationsOctober 1st, 2019